Form 4: MaxCyte Director Stanley C. Erck Executes Option and Sells Shares Under 10b5-1 Plan

Director Stanley C. Erck exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 1, 2024, Stanley C. Erck, a director of MaxCyte, Inc., exercised employee stock options to acquire 47,689 shares of common stock at a price of $0.04 per share.
• Simultaneously, Erck sold 47,689 shares of common stock at a weighted average price of $3.72 per share, with individual sales prices ranging from $3.61 to $3.755.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 12, 2024.
• Following these transactions, Erck directly owns 269,118 shares of MaxCyte common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged plan. There is no indication of positive or negative sentiment towards the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions. Directors often use 10b5-1 plans to avoid accusations of trading on inside information. The sale could be for personal financial management and may not reflect a change in the director's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a director, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates